H Kim, YS Hwang, M Kim, SB Park - RSC Medicinal Chemistry, 2021 - pubs.rsc.org
The use of covalent inhibitors in the field of drug discovery has attracted considerable attention in the 2000s. As a result, more than 50 covalent drugs are currently on the market …
S De Cesco, J Kurian, C Dufresne… - European Journal of …, 2017 - Elsevier
In the history of therapeutics, covalent drugs occupy a very distinct category. While representing a significant fraction of the drugs on the market, very few have been …
J Singh, RC Petter, TA Baillie, A Whitty - Nature reviews Drug discovery, 2011 - nature.com
Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug …
F Sutanto, M Konstantinidou, A Dömling - RSC medicinal chemistry, 2020 - pubs.rsc.org
Covalent inhibitors are recognized as an important component in drug discovery and therapeutics. Since the first appearance of covalent inhibitors in the late 18th century, the …
Highlights•High potencies and prolonged effects achievable with covalent drugs may result in less frequent dosing and improved therapeutic margins for patients.•Covalent inhibition …
AS Kalgutkar, DK Dalvie - Expert opinion on drug discovery, 2012 - Taylor & Francis
Introduction: The design of target-specific covalent inhibitors is conceptually attractive because of increased biochemical efficiency through covalency and increased duration of …
E De Vita - Future Medicinal Chemistry, 2021 - Taylor & Francis
In the first decade of targeted covalent inhibition, scientists have successfully reversed the previous trend that had impeded the use of covalent inhibition in drug development …
Covalent inhibition is a rapidly growing discipline within drug discovery. Many historical covalent inhibitors were discovered by serendipity, with such a mechanism of action often …
A Tuley, W Fast - Biochemistry, 2018 - ACS Publications
Covalent enzyme inhibitors are widely applied as biochemical tools and therapeutic agents. As a complement to categorization of these inhibitors by reactive group or modification site …